<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639480</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_EXA_301</org_study_id>
    <nct_id>NCT03639480</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia</brief_title>
  <official_title>A Double-blind, Randomized, Multi-center Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of CJ-30061 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Atorvastatin Combination Therapy in Hypertensive Patients With Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of CJ-30061 compared with amlodipine/valsartan
      combination therapy and valsartan/atorvastatin combination therapy in hypertensive patients
      with hyperlipidemia
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in siSBP</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Change in siSBP from baseline after 8 weeks of study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LDL-C</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Change in LDL-C from baseline after 8 weeks of study treatment</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine 10mg+Valsartan 160mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valsartan 160mg+Atorvastatin 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg</intervention_name>
    <description>Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine 10mg+Valsartan 160mg</intervention_name>
    <description>Amlodipine 10mg+Valsartan 160mg</description>
    <arm_group_label>Reference 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 160mg+Atorvastatin 40mg</intervention_name>
    <description>Valsartan 160mg+Atorvastatin 40mg</description>
    <arm_group_label>Reference 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 19 and 74 years

          -  Diagnosed with essintial hypertension(average siSBP ≥ 140mmHg) accompanying
             hyperlipidemia(LDL-C ≥ 100mg/dL) and were on or off treatment at Visit 1(screening)

          -  Decided to participate in the study and provided signed informed consent form
             voluntarily after receiving explanation of the objectives, methods, and effects of the
             study

        Exclusion Criteria:

          -  Severe hypertension defined as average siDBP ≥ 120mmHg or average siSBP ≥ 200mmHg at
             Visit 1(screening)

          -  The difference in BPs between those measured at the reference arm at Visit
             1(screening) was ≥ 10mmHg for siDBP or ≥ 20mmHg for siSBP

          -  LDL-C &gt; 250mg/dL or TG ≥ 400mg/dL at Visit 1(screening)

          -  Secondary hypertension

          -  Diagnosis of type 1 diabetes mellitus(DM) or uncontrolled DM(patients on insulin
             therapy or patients with HbA1c ≥ 9%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duk-Hyun Kang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>August 19, 2018</last_update_submitted>
  <last_update_submitted_qc>August 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

